Effect of CYP2C19 genotypes on the pharmacokinetic/pharmacodynamic relationship of rabeprazole after a single oral dose in healthy Chinese volunteers

European Journal of Clinical Pharmacology

Volumn 66, Issue 11, 2010, Pages 1165-1169

  Sheng, Yu Cheng ^a   Wang, Kun ^a   He, Ying Chun ^a   Yang, Juan ^a   Zheng, Qing Shan ^a  

^a SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

Author keywords

CYP2C19 genotype; NONMEM; Pharmacokinetics pharmacodynamics; Rabeprazole

Indexed keywords

CYTOCHROME P450 2C19; RABEPRAZOLE;

ADULT; ARTICLE; CHINESE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; GENOTYPE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PHARMACODYNAMICS; PHARMACOGENETICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; STOMACH PH;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADMINISTRATION, ORAL; ADULT; ANALYSIS OF VARIANCE; ARYL HYDROCARBON HYDROXYLASES; ASIAN CONTINENTAL ANCESTRY GROUP; DRUG ADMINISTRATION SCHEDULE; ENZYME INHIBITORS; GASTRIC ACIDITY DETERMINATION; GENOTYPE; HUMANS; HYDROGEN-ION CONCENTRATION; MALE; TIME FACTORS;

EID: 78649320286     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-010-0892-4     Document Type: Article

References (26)

1. S Pallotta F Pace S Marelli 2008 Rabeprazole: a second-generation proton pump inhibitor in the treatment of acid-related disease Expert Rev Gastroenterol Hepatol 2 4 509 522 1:CAS:528:DC%2BD1cXpt1elsLo%3D 10.1586/17474124.2.4.509 19072398
2. T Kita T Sakaeda T Baba N Aoyama M Kakumoto Y Kurimoto Y Kawahara N Okamura S Kirita M Kasuga K Okumura 2003 Different contribution of CYP2C19 in the in vitro metabolism of three proton pump inhibitors Biol Pharm Bull 26 3 386 390 1:CAS:528:DC%2BD3sXjsVaisrw%3D 10.1248/bpb.26.386 12612455
3. T Ishizaki Y Horai 1999 Review article: cytochrome P450 and the metabolism of proton pump inhibitors-emphasis on rabeprazole Aliment Pharmacol Ther 13 Suppl 3 27 36 1:CAS:528:DyaK1MXlvVGhurk%3D 10.1046/j.1365-2036.1999. 00022.x 10491726
4. M Miura S Satoh H Tada T Habuchi T Suzuki 2006 Stereoselective metabolism of rabeprazole-thioether to rabeprazole by human liver microsomes Eur J Clin Pharmacol 62 2 113 117 1:CAS:528:DC%2BD28XivFSgsrw%3D 10.1007/s00228-005-0077-8 16389533
5. K Adachi T Katsube A Kawamura T Takashima M Yuki K Amano S Ishihara R Fukuda M Watanabe Y Kinoshita 2000 CYP2C19 genotype status and intragastric pH during dosing with lansoprazole or rabeprazole Aliment Pharmacol Ther 14 10 1259 1266 1:CAS:528:DC%2BD3cXotV2jsb0%3D 10.1046/j.1365-2036.2000.00840.x 11012469
6. T Shimatani M Inoue T Kuroiwa J Xu H Mieno M Nakamura S Tazuma 2006 Acid-suppressive effects of rabeprazole, omeprazole, and lansoprazole at reduced and standard doses: a crossover comparative study in homozygous extensive metabolizers of cytochrome P450 2C19 Clin Pharmacol Ther 79 1 144 152 1:CAS:528:DC%2BD28XksVGluw%3D%3D 10.1016/j.clpt.2005.09.012 16413249 (Pubitemid 43069585)
7. YM Hu JM Xu Q Mei XH Xu SY Xu 2005 Pharmacodynamic effects and kinetic disposition of rabeprazole in relation to CYP2C19 genotype in healthy Chinese subjects Acta Pharmacol Sin 26 3 384 388 1:CAS:528:DC%2BD2MXisFGitrk%3D 10.1111/j.1745-7254.2005.00047.x 15715938 (Pubitemid 40388078)
8. Y Horai M Kimura H Furuie K Matsuguma S Irie Y Koga T Nagahama M Murakami T Matsui T Yao A Urae T Ishizaki 2001 Pharmacodynamic effects and kinetic disposition of rabeprazole in relation to CYP2C19 genotypes Aliment Pharmacol Ther 15 6 793 803 1:CAS:528:DC%2BD3MXks1Kitr4%3D 10.1046/j.1365-2036.2001.00980. x 11380317 (Pubitemid 32500425)
9. T Shimatani M Inoue T Kuroiwa Y Horikawa 2004 Rabeprazole 10 mg twice daily is superior to 20 mg once daily for night-time gastric acid suppression Aliment Pharmacol Ther 19 1 113 122 1:CAS:528:DC%2BD2cXhvVKjsrw%3D 10.1046/j.1365-2036.2003.01821.x 14687173 (Pubitemid 38125644)
10. U Klotz M Schwab G Treiber 2004 CYP2C19 polymorphism and proton pump inhibitors Basic Clin Pharmacol Toxicol 95 2 8 1:CAS:528:DC%2BD2cXmtlKisbc%3D 15245569
11. SM De Morais GR Wilkinson J Blaisdell UA Meyer K Nakamura JA Goldstein 1994 Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese Mol Pharmacol 46 4 594 598 7969038 (Pubitemid 24334747)
12. Z Desta X Zhao JG Shin DA Flockhart 2002 Clinical significance of the cytochrome P450 2C19 genetic polymorphism Clin Pharmacokinet 41 12 913 958 1:CAS:528:DC%2BD38XotlGisbg%3D 10.2165/00003088-200241120-00002 12222994
13. Y Shu HH Zhou 2000 Individual and ethnic differences in CYP2C19 activity in Chinese populations Acta Pharmacol Sin 21 3 193 199 1:CAS:528: DC%2BD3cXhvFSgtbY%3D 11324414
14. T Ishizaki DR Sohn K Kobayashi K Chiba KH Lee SG Shin T Andersson CG Regardh YC Lou Y Zhang, et al. 1994 Interethnic differences in omeprazole metabolism in the two S-mephenytoin hydroxylation phenotypes studied in Caucasians and Orientals Ther Drug Monit 16 2 214 215 1:STN:280: DyaK2c3nvVylsg%3D%3D 10.1097/00007691-199404000-00018 8009572
15. ZY Chen HT Xie QS Zheng RY Sun G Hu 2006 Pharmacokinetic and pharmacodynamic population modeling of orally administered rabeprazole in healthy Chinese volunteers by the NONMEM method Eur J Drug Metab Pharmacokinet 31 1 27 33 1:CAS:528:DC%2BD28XkvVCgt7k%3D 10.1007/BF03190639 16715780
16. JC Yang YF Yang YS Uang CJ Lin TH Wang 2009 Pharmacokinetic- pharmacodynamic analysis of the role of CYP2C19 genotypes in short-term rabeprazole-based triple therapy against Helicobacter pylori Br J Clin Pharmacol 67 5 503 510 1:CAS:528:DC%2BD1MXmtVyru70%3D 10.1111/j.1365-2125.2009.03393.x 19552744
17. L Zhang SL Beal LB Sheiner 2003 Simultaneous vs. sequential analysis for population PK/PD data. I. Best-case performance J Pharmacokinet Pharmacodyn 30 6 387 404 10.1023/B:JOPA.0000012998.04442.1f 15000421 (Pubitemid 38221931)
18. SC Sim C Risinger ML Dahl E Aklillu M Christensen L Bertilsson M Ingelman-Sundberg 2006 A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants Clin Pharmacol Ther 79 1 103 113 1:CAS:528: DC%2BD28XksVGltw%3D%3D 10.1016/j.clpt.2005.10.002 16413245 (Pubitemid 43069582)
19. RM Baldwin S Ohlsson RS Pedersen J Mwinyi M Ingelman-Sundberg E Eliasson L Bertilsson 2008 Increased omeprazole metabolism in carriers of the CYP2C19*17 allele; a pharmacokinetic study in healthy volunteers Br J Clin Pharmacol 65 5 767 774 1:CAS:528:DC%2BD1cXmsV2hsrw%3D 10.1111/j.1365-2125.2008. 03104.x 18294333 (Pubitemid 351535091)
20. T Nakamura M Yamamori T Sakaeda 2008 Pharmacogenetics of intestinal absorption Curr Drug Deliv 5 3 153 169 1:CAS:528:DC%2BD1cXnsF2jtbo%3D 10.2174/156720108784911749 18673259 (Pubitemid 351977879)
21. T Uno M Shimizu N Yasui-Furukori K Sugawara T Tateishi 2006 Different effects of fluvoxamine on rabeprazole pharmacokinetics in relation to CYP2C19 genotype status Br J Clin Pharmacol 61 3 309 314 1:CAS:528:DC%2BD28XislKhsbw%3D 10.1111/j.1365-2125.2005.02556.x 16487224 (Pubitemid 43382630)
22. I Ieiri Y Kishimoto H Okochi K Momiyama T Morita M Kitano T Morisawa Y Fukushima K Nakagawa J Hasegawa K Otsubo T Ishizaki 2001 Comparison of the kinetic disposition of and serum gastrin change by lansoprazole versus rabeprazole during an 8-day dosing scheme in relation to CYP2C19 polymorphism Eur J Clin Pharmacol 57 6-7 485 492 1:CAS:528:DC%2BD3MXotlyku7c%3D 11699613
23. N Shirai T Furuta Y Moriyama H Okochi K Kobayashi M Takashima F Xiao K Kosuge K Nakagawa H Hanai K Chiba K Ohashi T Ishizaki 2001 Effects of CYP2C19 genotypic differences in the metabolism of omeprazole and rabeprazole on intragastric pH Aliment Pharmacol Ther 15 12 1929 1937 1:CAS:528: DC%2BD38Xks1SrtA%3D%3D 10.1046/j.1365-2036.2001.01108.x 11736724 (Pubitemid 34014349)
24. JG Hatlebakk PO Katz DO Castell 1999 Medical therapy management of the refractory patient Gastroenterol Clin North Am 28 4 847 860 1:STN:280: DC%2BD3c7lvFehug%3D%3D 10.1016/S0889-8553(05)70093-5 10695005
25. K Adachi H Fujishiro T Katsube M Yuki M Ono A Kawamura MA Rumi M Watanabe Y Kinoshita 2001 Predominant nocturnal acid reflux in patients with Los Angeles grade C and D reflux esophagitis J Gastroenterol Hepatol 16 11 1191 1196 1:STN:280:DC%2BD387mvFKlug%3D%3D 10.1046/j.1440-1746.2001.02617.x 11903734 (Pubitemid 34088263)
26. M Sugimoto T Furuta N Shirai M Kajimura A Hishida M Sakurai K Ohashi T Ishizaki 2004 Different dosage regimens of rabeprazole for nocturnal gastric acid inhibition in relation to cytochrome P450 2C19 genotype status Clin Pharmacol Ther 76 4 290 301 1:CAS:528:DC%2BD2cXotlCmtL0%3D 10.1016/j.clpt.2004. 06.008 15470328 (Pubitemid 39313119)